A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c)
level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day
(QD) administration to type 2 diabetic patients who have failed to achieve adequate glycemic
control on oral antidiabetic drugs (OADs).
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin Lispro Isophane insulin, insulin lispro drug combination 50:50